RxDoctor Payments Data

Tanda Hicks

Family · Wheatland, WYNPI 1053312504

Payments from drug & device makers

$304in general payments, 2019–2025

Across 19 payments — averaging $15.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$85
  • Lilly USA, LLC$74
  • Amgen$49
  • AstraZeneca$34
  • Novartis$21
  • Novo Nordisk$15
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$304100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Exact Sciences5$85
Lilly USA, LLC5$74
Amgen3$49
AstraZeneca2$34
Novartis1$21
Novo Nordisk1$15
Merck1$14
AbbVie1$12

How this compares

$304 in reported general payments places this provider in the 55th percentile of 284 family providers in Wyoming.

See all family providers in Wyoming

Medicare billing

Part B allowed, 2024
$64,357
Medicare patients
342
Services billed
1,299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban119$79,457
OzempicSemaglutide60$63,892
MounjaroTirzepatide43$48,154
XareltoRivaroxaban49$32,750
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$23,228
Janumet XrSitagliptin Phos/Metformin Hcl24$19,599
JanumetSitagliptin Phos/Metformin Hcl32$17,072
Breo ElliptaFluticasone/Vilanterol36$15,279
FarxigaDapagliflozin Propanediol14$13,589
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog36$12,878
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$8,470
JanuviaSitagliptin Phosphate13$8,401
SynthroidLevothyroxine Sodium65$5,867
Lantus SolostarInsulin Glargine,hum.Rec.Anlog49$4,500
Levothyroxine Sodium474$4,285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$63,89260 claims
Lilly USA, LLCMounjaro$74$48,15443 claims
MerckJanumet Xr, Janumet, Januvia$14$45,07269 claims
AstraZenecaFarxiga$34$13,58914 claims
AbbVieSynthroid, Armour Thyroid$12$6,75883 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 284 family providers in Wyoming.

Other family in Wheatland

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →